The emerging markets will comprise 1/3 of global pharma by 2017

Dr. Gurpreet Sandhu, Reva Pharmachem Managing Director, shared the following in regard to Drug Manufacturing in Russia:

“A <<more achievement for less cost>> focus has forced many drug companies to think about the possibility of moving some of its operations to low-cost emerging markets. Emerging markets are the promised land and growth engine of the pharmaceutical industry. They will comprise 1/3 of global pharma by 2017.”

Dr. Gurpreet Sandhu will speak about emerging Pharma markets on December 10, at the Kakushin Webinar “Drug Manufacturing in Russia”.

The past two decades have been marked by a real breakthrough in Russia. To sum up the past 20 years, the Russian pharmaceutical market has grown in size fivefold and exceeds 20 billion US dollars in consumer prices. The range of products available in the market has also expanded 1.4 times in terms of product mix and 3.5 times regarding number of packages.

Kakushin Webinars is committed to bring top-level know-how related to the Russian pharmaceutical industry.

Why? Dr Gurpreet Sandhu offers the answer:

“The winners in emerging markets will be those companies that know how to best balance their global competences with tailored approaches for local markets. There is no <<one-sizefits- all>> approach to emerging markets – each region / market is a challenge.”

If you want your company to tailor its approach to the Russian local needs, join the Kakushin webinar.

The full webinar program may be downloaded here >>